Zhan MX - Search Results

1

Activation of MET promotes resistance to sorafenib in hepatocellular carcinoma cells via the AKT/ERK1/2-EGR1 pathway.

Xiang QF, Zhan MX, Li Y, Liang H, Hu C, Huang YM, Xiao J, He X, Xin YJ, Chen MS, Lu LG. Xiang QF, et al. Among authors: zhan mx. Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):83-89. doi: 10.1080/21691401.2018.1543195. Artif Cells Nanomed Biotechnol. 2019. PMID: 30663411 Free article.

2

[Prognostic significance of serum level of vascular endothelial growth factor receptor-2 in hepatocellular carcinoma patients after transcatheter arterial chemoembolization].

Meng QW, Li Y, Hu BS, Shao PJ, Zhan MX, Yu XY, Lu LG. Meng QW, et al. Among authors: zhan mx. Zhonghua Yi Xue Za Zhi. 2013 Jan 29;93(5):341-4. Zhonghua Yi Xue Za Zhi. 2013. PMID: 23660204 Chinese.

3

[Expression of serum microRNAs (miR-222, miR-181, miR-216) in human hepatocellular carcinoma and its clinical significance].

Zhan MX, Li Y, Hu BS, Shao PJ, Meng QW, He X, Huang JW, Lu LG. Zhan MX, et al. Zhonghua Yi Xue Za Zhi. 2013 Jun 18;93(23):1830-2. Zhonghua Yi Xue Za Zhi. 2013. PMID: 24124720 Chinese.

4

[Clinical application of serum Golgi protein 73 in the diagnosis and progress of hepatocellular carcinoma].

Zhao Y, Li Y, Hu B, He X, Huang J, Zhan M, Lu L. Zhao Y, et al. Zhonghua Yi Xue Za Zhi. 2014 Feb 11;94(5):390-2. Zhonghua Yi Xue Za Zhi. 2014. PMID: 24746091 Chinese.

5

Sorafenib continuation after first disease progression could reduce disease flares and provide survival benefits in patients with hepatocellular carcinoma: a pilot retrospective study.

Fu SR, Zhang YQ, Li Y, Hu BS, He X, Huang JW, Zhan MX, Lu LG, Li JP. Fu SR, et al. Among authors: zhan mx. Asian Pac J Cancer Prev. 2014;15(7):3151-6. doi: 10.7314/apjcp.2014.15.7.3151. Asian Pac J Cancer Prev. 2014. PMID: 24815462 Free article.

6

Serum microRNA-210 as a predictive biomarker for treatment response and prognosis in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.

Zhan M, Li Y, Hu B, He X, Huang J, Zhao Y, Fu S, Lu L. Zhan M, et al. J Vasc Interv Radiol. 2014 Aug;25(8):1279-1287.e1. doi: 10.1016/j.jvir.2014.04.013. Epub 2014 Jun 13. J Vasc Interv Radiol. 2014. PMID: 24935355

7

Genetic variants in the KDR gene is associated with the prognosis of transarterial chemoembolization treated hepatocellular carcinoma.

Zheng YB, Huang JW, Zhan MX, Zhao W, Liu B, He X, Li Y, Hu BS, Lu LG. Zheng YB, et al. Among authors: zhan mx. Tumour Biol. 2014 Nov;35(11):11473-81. doi: 10.1007/s13277-014-2478-8. Epub 2014 Aug 16. Tumour Biol. 2014. PMID: 25123269

8

The relationship of kinase insert domain receptor gene polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients treated with sorafenib.

Zheng YB, Zhan MX, Zhao W, Liu B, Huang JW, He X, Fu SR, Zhao Y, Li Y, Hu BS, Lu LG. Zheng YB, et al. Among authors: zhan mx. Med Oncol. 2014 Oct;31(10):209. doi: 10.1007/s12032-014-0209-z. Epub 2014 Sep 3. Med Oncol. 2014. PMID: 25182707

9

Usp7 promotes medulloblastoma cell survival and metastasis by activating Shh pathway.

Zhan M, Sun X, Liu J, Li Y, Li Y, He X, Zhou Z, Lu L. Zhan M, et al. Biochem Biophys Res Commun. 2017 Mar 4;484(2):429-434. doi: 10.1016/j.bbrc.2017.01.144. Epub 2017 Jan 27. Biochem Biophys Res Commun. 2017. PMID: 28137592

10

DT-13 synergistically potentiates the sensitivity of gastric cancer cells to topotecan via cell cycle arrest in vitro and in vivo.

Du H, Liu Y, Chen X, Yu X, Hou X, Li H, Zhan M, Lin S, Lu L, Yuan S, Sun L. Du H, et al. Eur J Pharmacol. 2018 Jan 5;818:124-131. doi: 10.1016/j.ejphar.2017.10.014. Epub 2017 Nov 5. Eur J Pharmacol. 2018. PMID: 29037767

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

147 results

Search Page

Filters